RMC-6236 (Unresectable or Metastatic Colorectal Cancer or Pancreatic Cancer)

RMC-6236 (Unresectable or Metastatic Colorectal Cancer or Pancreatic Cancer)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with metastatic or unresectable colorectal cancer; OR
  • Are diagnosed with metastatic pancreatic cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

What is Involved?

Description

If you choose to join this study, you will:
  • Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab
  • Have a tumor biopsy done, if necessary
  • Have blood draws
  • Have imaging scans (CT or MRI)

Study Details

Full Title

Study of RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma– Subprotocol A

Principal Investigator

John
Strickler

Protocol Number

PRO00115657

NCT ID

NCT06445062

Phase

I/II

Enrollment Status

Open to Enrollment
ClinicalTrials.gov